| abstract |
The present invention relates to the use of the MEK inhibitor compound 6- (4-bromo-2-fluorophenylamino) -7-fluoro-3-methyl-3H-benzoimidazole- ) -Amide or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising an IGF1R inhibitor antibody A, a pharmaceutical composition comprising such a combination, a therapeutically effective amount of such a combination, to a subject in need thereof And to the use of such a combination to treat cancer. |